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Cerebral microbleeds, detected using magnetic 
resonance imaging (MRI), are considered 
an imaging marker of cerebral small vessel 
disease [1]. Microbleeds can occur throughout 
the brain, and their location is thought to 
reflect the underlying pathology [1]. Typically, 
microbleeds in the deep and infratentorial 
regions are thought to reflect hypertensive 
arteriopathy [1,2]. In contrast, lobar cerebral 
microbleeds are associated with cerebral 
amyloid angiopathy (CAA), which is a build-up 
of beta-amyloid in the cortical and subcortical 
vessels of the brain that can lead to either 
small infarctions or vessel rupture [3-6]. When 
vessels rupture, the results are small cerebral 
microbleeds or – clinically more devastating - 
large, symptomatic intracerebral hemorrhage 
(ICH). In addition to patients with lobar ICH, 
CAA frequently coexists with Alzheimer’s 
disease (AD) pathology [7]. Like in AD, the 
strongest known genetic risk factor for CAA and 
CAA-related hemorrhages is Apolipoprotein E 
(APOE), but, in contrast to AD, both the APOE 
e4 and the APOE e2 variant alleles increase risk 
compared to the wildtype e3e3.
Within individual patients with CAA, the 
distribution of vascular beta-amyloid appears 
patchy, and the resulting hemorrhagic 
outcomes tend to cluster [8]. Though CAA 
can occur in any lobar region of the brain [6], 
the posterior lobar regions seem more prone 
to severe vascular beta-amyloid depositions 
[6,9]. Likewise, the resulting CAA-related 
ICH and cerebral microbleeds have primarily 
posterior lobar distributions, with the occipital 
lobe, in particular, exceptionally vulnerable 
to hemorrhagic outcomes [8,10,11]. Several 
elegant studies in CAA patients have provided 
strong evidence that microbleeds occur in 
areas of high loads of vascular amyloid [2,4,12]. 
Aside from patient populations, microbleeds 
are frequently observed in seemingly 
asymptomatic, general population [13-16]. The 
predominantly posterior distribution of lobar 
microbleeds has also been reported in these 
populations [13,17]. However, the underlying 
pathologies of microbleeds in this group is 
still largely unconrmed via amyloid imaging 
or autopsy, because these techniques are not 
widely available in the general population. 
One case-control study of AD and preclinical-
AD patients demonstrated that healthy 
controls with lobar cerebral microbleeds had 
significantly higher loads of beta-amyloid than 
those without lobar microbleeds [11], and that 
incident lobar microbleeds in healthy controls 
are associated with both carriership of APOE 
e4 allele and higher load of beta-amyloid 
[18]. Moreover, the healthy controls who 
were e4 carriers had higher amyloid retention 
compared to those who were non-carriers [19]. 
In a recent paper, posterior distribution of lobar 
microbleeds within the entire community-
dwelling Rotterdam Study population was 
found, but those among this population, who 
were carriers of the APOE e2 or e4 alleles, had 
microbleeds that occurred closer together and 
had an ever higher proportion of microbleeds 
in the occipital lobe compared to persons with 
APOE e3e3 genotype [20]. 
Though APOE e2 and e4 alleles are both 
associated with presence of CAA and risk 
of adverse outcomes due to CAA [21,22], 
each allele is associated with the pathology 
differently. Specifically, e4 allele is suggested 
to relate to CAA type 1, which includes amyloid 
depositions in the capillaries, whereas e2 allele 
is overrepresented among CAA type 2, which is 
devoid of amyloid depositions in the capillaries 
[23]. Moreover, the APOE e2 and e4 variants 
are thought to lead to hemorrhagic outcomes 
1Department of Epidemiology,
 Erasmus MC University Medical Center,
 3000 CA, Rotterdam, ZH, Netherlands
2Department of Radiology,
 Erasmus MC University Medical Center,
 3000 CA, Rotterdam, ZH, Netherlands
3Department of Neurology,
 Erasmus MC University Medical Center,
 3000 CA, Rotterdam, ZH, Netherlands
Elizabeth Loehrer1,
Meike W. Vernooij1,2,
M. Arfan Ikram1,2,3*
Received 09 May 2014 
accepted 29 May 2014
CEREBRAL MICROBLEEDS: 
SPATIAL DISTRIBUTION 
IMPLICATIONS
Abstract
Cerebral microbleeds are considered an imaging marker of cerebral small vessel disease. The location of 
microbleeds is thought to reflect the underlying pathology. Microbleeds in the deep and infratentorial region are 
thought to reflect hypertensive arteriopathy whereas lobar microbleeds are associated clinically with cerebral 
amyloid angiopathy (CAA). Aside from patient populations, microbleeds are frequently observed in seemingly 
asymptomatic populations. Moreover, many elderly, both in clinical and preclinical populations, have multiple 
coexisting pathologies in their brains, which complicates the interpretation of cerebral microbleeds, especially 
early in the clinical course. In this commentary, we discuss the influence of the strongest genetic risk factor for 
CAA, Apolipoprotein E (APOE), in the spatial distribution of microbleeds, and we additionally address issues in 
interpretation and implication of the location of microbleeds in clinical and asymptomatic populations.
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through different mechanisms. Studies in CAA 
and AD patients have shown that while the e4 
allele carriers are shown to accumulate more 
beta-amyloid and faster, leading to a thickening 
and eventual rupture of vessel walls, e2 carriers 
are thought to have increased vessel fragility, 
leading to easier rupture of vessels without an 
increased amyloid burden compared to normal 
genotype [21,22,24-26]. Thus, these two alleles 
seem to result in distinct pathways, both of 
which are more susceptible to hemorrhagic 
outcomes compared to the wild-type 
genotype. The described posterior distribution 
of beta-amyloid deposition [6,9], lobar ICH 
[8], and microbleeds [8] in CAA seems to 
suggest that the posterior circulating territory 
is disproportionately affected compared to 
other vascular territories, though the specific 
reason for this remains unclear. Taken together, 
our recent findings are likely representing a 
particularly vulnerable posterior circulating 
territory among all persons coupled with 
increased susceptibility to adverse outcomes 
among APOE risk allele carriers, leading to even 
more events in that region than we observe 
in the wild-type APOE. When combined with 
findings from other studies, the available 
evidence supports the notion that APOE has a 
subtle effect on the pathology underlying lobar 
microbleeds in both patient and asymptomatic 
general populations. 
Clinically, only persons with multiple 
strictly lobar bleeds, that is, microbleeds or 
ICH only in the lobar location, are included 
in the diagnostic criteria of (probable) CAA 
[27]. The reality is that many elderly, both 
in clinical and preclinical populations, have 
multiple coexisting pathologies in the brain 
[28-31]. When microbleeds occur in both the 
lobar and deep and/or infratentorial regions 
in the same person, the underlying pathology 
responsible for the bleeds is less clear. Mixed 
lobar/deep/infratentorial microbleeds have 
been reported in patient and population-based 
settings, and they are typically attributed 
to hypertensive arteriopathy in situations 
when the driving pathology is not known 
[1,13,15,30,32,33]. In the population-based 
Rotterdam Study, we have shown that even 
persons with any lobar microbleeds (with or 
without microbleeds in other locations) show 
a posterior predominant distribution similar 
to CAA population distributions and are likely 
the result of underlying CAA [17,20]. Our 
most recent work also showed that among all 
microbleeds, incident microbleeds occurred 
in close proximity to prevalent microbleeds 
within participants, particularly among APOE 
risk allele carriers [20]. Though the microbleeds 
in this analysis were primarily lobar, we did 
observe clustering between microbleeds that 
technically fell on opposite sides of regional 
boundaries, i.e., deep and lobar (Figure 1) [20]. 
We can imagine that microbleeds that occur 
very close together share the same pathology 
(or pathologies), and reflect vulnerability in a 
specific location, even if they are technically 
in different brain regions. Though this specific 
scenario has not been described extensively 
in literature, there is some evidence that the 
typical strict division between lobar and deep 
microbleeds might need some rethinking, 
or at the very least, further investigation. For 
example, though APOE variant alleles have 
typically been studied in regard to lobar 
Figure 1.  Magnetic resonance images of baseline (A) and follow-up (B) scans of one participant, which demonstrates that microbleeds can occur close together but on 
opposite sides of the lobar/deep-border. In this instance, the prevalent microbleed (arrow in A) would be rated as “deep”, whereas the incident microbleed (arrow 
in B) would be rated as “lobar”. The question is whether these microbleeds occurred due to different pathologies, or due to one causal factor. 
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hemorrhages and amyloid related pathologies 
(i.e. CAA and AD), two recent meta-anlaysis 
have shown that carriership of the APOE e4 
allele increases risk of both lobar and deep 
microbleeds [34,35].
In the same light, cerebellar microbleeds 
also remain difficult to classify. Infratentorial 
microbleeds, including cerebellar microbleeds, 
are usually attributed to hypertensive 
arteriopathy [1,2,36]. However, cerebellar 
microbleeds are also allowed to be present 
for diagnosis of probable CAA, though beta-
amyloid deposition is thought to be present 
in the infratentorial regions only in the severe 
cases of CAA [36,37]. At least one study of 
ICH patients observed cerebellar microbleeds 
in persons with probable CAA, persons with 
strictly deep ICH, and persons with mixed deep 
and lobar bleeds, highlighting the fact that 
these microbleeds do not seem to be specific 
to a particular pathology [30]. When cerebellar 
microbleeds are observed in the general 
population, they are usually attributed to 
hypertensive risk factors [15], but the cause of 
these bleeds may be misattributed, particularly 
when they are in brains with many microbleeds 
(both lobar and deep). In clinical settings, the 
difficulty in interpreting mixed microbleeds is 
transposed to the interpretation of intracerebral 
hemorrhages that occur at the border of deep 
and lobar regions, or transgress this border. 
Therefore, the clinical management of these 
hemorrhages is not straightforward. Ideally, 
microbleeds could be used as a marker of 
underlying pathology and lead to intervention 
prior to a major clinical event. At the moment, 
the main challenge with interpreting 
microbleeds is that it is unclear if a singular, 
advanced pathology is responsible for bleeds 
in multiple regions, whether mixed pathologies 
are present and operating concurrently within 
the same brain, or whether mixed pathologies 
interact with each other, resulting in a distinct 
causal mechanism for hemorrhagic outcomes. 
Understanding of the causes and relevance of 
the spatial distribution of cerebral microbleeds 
is still lacking in both patient and asymptomatic 
populations. Though clinical studies have 
provided ample knowledge on microbleeds 
to date, they tend to focus on severe and 
homogenous patients. More typical, elderly with 
mixed pathologies, are an important group to 
study as they could lend crucial insight into our 
understanding of the progression of cerebral 
small vessel disease to symptomatic outcomes. 
As new minimally-invasive amyloid imaging 
techniques start to become more accessible, 
researchers can address many remaining 
questions regarding the involvement of beta-
amyloid in lobar and non-lobar microbleeds in 
asymptomatic persons. Population-based studies 
are optimal to study asymptomatic persons 
with mixed microbleeds to untangle the causal 
mechanism(s) of these bleeds, and to identify the 
predominant implications of microbleeds that 
appear early in the clinical course.
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